In a world where people live so long that their organs wear out, Cordis fund manager Jacob Celermajer has been buying up companies that tackle some of the world’s most chronic diseases.

-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement ...

Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device Helius Medical Technologies, Inc ...

Helius Medical Technologies, Inc. Announces Authorized Claim For Payment By Major Healthcare Payer For Its Portable Neuromodulation Stimulator (Pons®) Device Date 2025-06-11 07:16:02 ...

Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device ...

About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform ...

Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device 11-06-2025 -Aetna authorizes claim for ...

Thus, Inspire Medical Systems has an ROCE of 7.5%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 10%. See our latest analysis for Inspire ...

Inspire Medical Systems, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 28.9% compared with the industry’s 25.2%. Shares of the company have lost 9.5% ...

A month has gone by since the last earnings report for Inspire Medical Systems (INSP). Shares have lost about 14.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...